BASINGSTOKE, England and PHILADELPHIA, October 25 /PRNewswire/ --

- Enhances the Availability of Information for Shire Marketed Medicines

Bolstering its commitment to transparency in the reporting of clinical
trial study results, Shire plc, the global specialty biopharmaceutical
company, announced today the creation and availability of a new website that
offers access to specific Shire-sponsored clinical trials. The new site
provides scientific, non-promotional summaries of clinical trials in a
consistent format, and is available at http://www.ShireStudyResults.org as
well as through a link on the Shire corporate website at http://www.Shire.com
and through the previously established industry sponsored site
http://www.ClincalStudyResults.org.

"The creation of this new website helps us achieve our goal to ensure
that patients and their families, as well as physicians and other healthcare
providers, have access to accurate information related to Shire medicines,"
said Eliseo Salinas MD, Chief Scientific Officer for Shire. "It's important
for patients and their caregivers to understand all aspects associated with
the treatment options they may be considering, and this new tool, which
offers clinical trial data dating back to 2002, provides a central source to
this information for Shire-sponsored trials of our medicines."

Shire Global Medical Affairs created this new website and Shire's
Research & Development Compliance team is responsible for its content and
maintenance.

Shire Plc

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit and hyperactivity
disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and
renal diseases. The structure is sufficiently flexible to allow Shire to
target new therapeutic areas to the extent opportunities arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are
focused on products in niche markets with strong intellectual property
protection either in the US or Europe. Shire believes that a carefully
selected portfolio of products with strategically aligned and relatively
small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:
http://www.shire.com

"Safe Harbor" Statement Under the Private Securities Litigation Reform
Act of 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, Shire's results could be
materially affected. The risks and uncertainties include, but are not limited
to, risks associated with: the inherent uncertainty of pharmaceutical
research, product development (including the successful development of
JUVISTA(R) (Human TGFbeta3)), manufacturing and commercialization (including 
the launch and establishment in the market of VYVANSE); the impact of
competitive products, including, but not limited to the impact of those on
Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; 
patents, including but not limited to, legal challenges relating to Shire's 
ADHD franchise; government regulation and approval, including but not limited
to the expected product approval date of INTUNIV(TM) (guanfacine) extended
release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire's
ability to secure new products for commercialization and/or development;
Shire's ability to benefit from its acquisition of New River Pharmaceuticals
Inc.; and other risks and uncertainties detailed from time to time in Shire
plc's filings with the Securities and Exchange Commission, particularly Shire
plc's Annual Report on Form 10-K for the year ended December 31, 2006.